nVision Medical Company
.jpg)
Acquired by Boston Scientific. nVision developed the first and only device cleared by the U.S. Food and Drug Administration to collect cells from the fallopian tubes, offering a potential platform for earlier diagnosis of ovarian cancer. Recent studies have confirmed that several major types of ovarian cancer appear to originate from the fallopian tubes.
Headquarters:
San Bruno, California, United States
Total Funding:
$16,405,000
Founded Date:
01-01-2009
Employee Number:
1-10
Last Funding Type:
Series B
Investors Number:
9
Last Funding Date:
2016-07-21
Funding Status:
M&A
Estimated Revenue:
$1M to $10M
Industry:
General Health Care